Cortagen

How does Cortagen work?

Cortagen is a Khavinson short peptide proposed to act primarily in the central nervous system — with secondary effects reported in cardiac and immune tissue — by modulating tissue-specific gene expression and chromatin/heterochromatin structure. The molecular basis put forward is direct, site-specific binding of short peptides to DNA. The points below are hypotheses drawn from preclinical animal and in-vitro models, not established human mechanisms.

1. Tissue-Specific Gene Expression [1][3]. Cortagen is proposed to modulate tissue-specific gene expression. A cDNA-microarray study found that five days of Cortagen injections in mice altered the expression of roughly 110 known cardiac genes, with effects partly shared with and partly distinct from Vilon, Epitalon, and melatonin (Anisimov et al. 2004); a 2021 systematic review situates Cortagen within this peptide–gene-regulation framework (Khavinson et al. 2021).
2. Direct DNA Binding [2]. The molecular basis proposed for these effects is site-specific binding of short Khavinson peptides to DNA, modulating endonuclease activity (Khavinson et al. 2011).
3. Heterochromatin Remodeling [4]. In aging cells, Cortagen has been associated with epigenetic remodeling of 'aged' heterochromatin (Lezhava et al. 2015).
4. Neural Inflammatory Balance (hypothesized). In preclinical neural-tissue models, Cortagen is associated with balancing pro- versus anti-inflammatory signaling, oxidative-stress regulation, and nerve-tissue repair signaling. These remain hypotheses from animal and in-vitro work, not confirmed human mechanisms.

What is Cortagen researched for?

Cortagen's research base is entirely preclinical — rodent and in-vitro — and comes largely from the Khavinson research lineage. There are no human randomized controlled trials. The findings below should be read as early-stage, largely single-lineage preclinical signals, not clinical evidence.

1. Cardiac Gene-Expression Profiling [1]. cDNA-microarray analysis after five days of Cortagen injections in CBA mice showed changes in roughly 110 known cardiac genes, compared against Vilon, Epitalon, and melatonin to map common and specific effects (Anisimov et al. 2004). Preclinical.
2. Molecular Mechanism — Peptide–DNA Binding [2]. Site-specific binding of short Khavinson peptides to DNA, modulating endonuclease activity, provides a proposed molecular basis for the gene-expression effects (Khavinson et al. 2011).
3. Heterochromatin and Aging [4]. Epigenetic remodeling of 'aged' heterochromatin in aging cells has been associated with Cortagen (Lezhava et al. 2015).
4. Systematic-Review Context [3]. A 2021 open-access systematic review of peptide regulation of gene expression includes Cortagen among the short peptides surveyed (Khavinson et al. 2021).

How is Cortagen dosed?

There is no validated or FDA-approved dose for Cortagen. It is handled as a research-use-only lyophilized powder, and the published work is preclinical animal and in-vitro research rather than human dosing studies.

Because no controlled human dosing studies exist, there is no established human dose, and any figure circulated for injectable Cortagen is extrapolated rather than validated. Researchers handling the lyophilized powder reconstitute it with bacteriostatic or sterile water (see storage below); any volume chosen is a generic handling convenience, not a dosing recommendation. Prof. Peptide deliberately does not publish an injectable mg or mg/kg schedule — none has been validated in controlled research.

What are the side effects of Cortagen?

Cortagen's human safety profile is not characterized. The available evidence is entirely preclinical (rodent and in-vitro), so there is no controlled human adverse-event data to summarize. This is a Research Use Only compound and is not intended for human consumption; nothing here should be read as human-use guidance. The honest summary is that human tolerability, interactions, and long-term safety are simply unknown.

How should Cortagen be stored?

1. Lyophilized (powder) form: store cold and desiccated, protected from light. Freeze at -20°C for long-term storage; 2–8°C is acceptable short-term.
2. Reconstitute with bacteriostatic or sterile water for injection. Add the water slowly down the inside wall of the vial and swirl gently — do not shake.
3. Reconstituted solution: refrigerate at 2–8°C and keep protected from light.
4. Protect from light at all times; store in original packaging.
5. Discard if the solution is cloudy, discolored, or contains particles.

What are the limitations of Cortagen research?

This is the most important section to read carefully. The Cortagen evidence base is entirely preclinical — rodent and in-vitro — and there are no human clinical trials.

Where to source Cortagen

Cortagen is not approved for human use and is sold by specialty research peptide vendors for laboratory use only. Quality varies across vendors — verify a Certificate of Analysis before purchase.

Cortagen FAQ

References

1. Anisimov SV, Boheler KR, Khavinson VKh, Anisimov VN. Modulatory effect of the tetrapeptide Cortagen on cardiac gene expression in mice (cDNA microarray). Neuro Endocrinol Lett. 2004;25(1-2):87-93. PMID 15159690. https://pubmed.ncbi.nlm.nih.gov/15159690/
2. Khavinson VKh, Fedoreyeva LI, Vanyushin BF. Site-specific binding of short peptides with DNA modulates endonuclease activity. Bull Exp Biol Med. 2011;151(1):66-70. PMID 22442805. https://pubmed.ncbi.nlm.nih.gov/22442805/
3. Khavinson VK, et al. Peptide Regulation of Gene Expression: A Systematic Review. Molecules. 2021;26(22):7053. PMID 34834147. (Open Access) https://pubmed.ncbi.nlm.nih.gov/34834147/
4. Lezhava T, et al. Epigenetic Regulation of “Aged” Heterochromatin by Peptide Bioregulator Cortagen. Int J Pept Res Ther. 2015;21:157-163. DOI 10.1007/s10989-014-9443-7. https://doi.org/10.1007/s10989-014-9443-7

Published Studies